Successful Phase III Trials
Announced two successful Phase III trials: FORTIFY trial of BBP-418 in limb-girdle muscular dystrophy type 2i and CALIBRATE trial of encaleret in autosomal dominant hypocalcemia type 1, both exceeding expectations.
Attruby's Market Performance
Delivered 5,259 unique patient prescriptions to 1,355 unique healthcare providers, generating $108.1 million in net product sales this quarter, with a goal of achieving a 30-35% market share.
Expansion and Growth Strategy
Continued expansion efforts with Beyonttra in Europe and plans to leverage real-world evidence studies. Preparing for potential new launches in the pipeline, including encaleret, BBP-418, and infigratinib.
Strong Financial Position
Reported $120.7 million in total revenues for Q3 2025 and ended the quarter with $645.9 million in cash, cash equivalents, and marketable securities.